Status:
NOT_YET_RECRUITING
NMBA Reversal and Postoperative Urinary Retention
Lead Sponsor:
Beth Israel Deaconess Medical Center
Conditions:
Neuromuscular Blocking Agents
Urinary Retention After Procedure
Eligibility:
All Genders
18+ years
Brief Summary
In this single-center retrospective cohort study of adult patients who underwent surgery under general anesthesia at Beth Israel Deaconess Medical Center between September 2016 and January 2024, the a...
Eligibility Criteria
Inclusion
- Adult patients
- Non-urinary system surgery
- General anesthesia
- Use of rocuronium or vecuronium for neuromuscular blockade
- Neuromuscular blockade reversal with sugammadex or neostigmine (with atropine and/or glycopyrrolate)
- Postoperative admission to the post-anesthesia care unit (PACU)
Exclusion
- American Society of Anesthesiologists (ASA) physical status ≥ V
- Emergency reversal with sugammadex (≥ 16 mg/kg of sugammadex)
- Presence of foley or suprapubic catheter before or after the procedure
- Prior history of bladder resection surgery
- Observations with missing data for pre-specified confounding variables
Key Trial Info
Start Date :
May 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2026
Estimated Enrollment :
70000 Patients enrolled
Trial Details
Trial ID
NCT06948409
Start Date
May 1 2025
End Date
August 1 2026
Last Update
April 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215